肿瘤细胞治疗研究
英文原题：Clinical and Translational Advances in Glioma Immunotherapy.
胶质瘤对免疫检查点阻断具有高度治疗抵抗性，而免疫检查点阻断是一种彻底改变了许多肿瘤治疗的免疫治疗模式。
胶质瘤对免疫检查点阻断具有高度治疗抵抗性，而免疫检查点阻断是一种彻底改变了许多肿瘤治疗的免疫治疗模式。与此同时，技术创新极大地加速了免疫治疗方法的开发，例如个性化肿瘤特异性疫苗生产、树突状细胞疫苗制备、患者个体化靶点选择以及嵌合抗原受体和T细胞受体T细胞制备。本文综述了胶质瘤免疫治疗近期的临床和转化进展，重点关注靶点及其同源免疫受体衍生物，以及改善瘤内T细胞效应功能的理念。
Gliomas are highly treatment refractory against immune checkpoint blockade, an immunotherapeutic modality that revolutionized therapy for many tumors. At the same time, technological innovation has dramatically accelerated the development of immunotherapeutic approaches such as personalized tumor-specific vaccine production, dendritic cell vaccine manufacture, patient-individual target selection and chimeric antigen receptor, and T cell receptor T cell manufacture. Here we review recent clinical and translational advances in glioma immunotherapy with a focus on targets and their cognate immune receptor derivates as well as concepts to improve intratumoral T cell effector functions.
MEMBER ACCOUNT
登录成功会直接打开下一页。
